HC Wainwright reaffirmed their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q2 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.59) EPS.
Other equities research analysts have also issued reports about the stock. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Leerink Partners upped their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $9.80.
Read Our Latest Analysis on Aquestive Therapeutics
Aquestive Therapeutics Trading Up 7.5 %
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same quarter in the prior year, the business earned ($0.03) earnings per share. Equities research analysts forecast that Aquestive Therapeutics will post -0.48 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. bought a new position in Aquestive Therapeutics in the second quarter worth about $27,000. nVerses Capital LLC bought a new position in shares of Aquestive Therapeutics in the 3rd quarter worth approximately $28,000. SG Americas Securities LLC purchased a new position in shares of Aquestive Therapeutics in the 1st quarter valued at approximately $54,000. The Manufacturers Life Insurance Company bought a new stake in shares of Aquestive Therapeutics during the second quarter valued at approximately $76,000. Finally, Financial Advocates Investment Management grew its stake in Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after purchasing an additional 14,000 shares during the period. 32.45% of the stock is currently owned by institutional investors.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Read More
- Five stocks we like better than Aquestive Therapeutics
- How to Plot Fibonacci Price Inflection Levels
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- How to Calculate Retirement Income: MarketBeat’s Calculator
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Which Wall Street Analysts are the Most Accurate?
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.